177Lu-CTR-FAPI for the Treatment of Thyroid Cancer

This study is testing a new targeted radiation treatment called 177Lu-CTR-FAPI for people with thyroid cancer that no longer responds to standard treatments like radioactive iodine or targeted drug therapies. The treatment uses a special molecule that seeks out cancer cells and delivers radiation directly to them. **You may be eligible if...** - You have a confirmed diagnosis of thyroid cancer that has stopped responding to radioactive iodine treatment - Your cancer has measurable tumors on imaging scans - You have already had surgery to remove neck tumors that could be removed, but still have disease that cannot be surgically treated - A special PET scan shows your tumors absorb the targeting molecule strongly - You are generally well enough to carry out daily activities (performance status 0–2) - Your life expectancy is more than 6 months **You may NOT be eligible if...** - Some of your tumors do not show uptake on the special PET scan - You have had prior radiation therapy other than radioactive iodine - You recently had cancer treatment, major surgery, or heart attack/stroke (within 8 weeks) - You are pregnant or breastfeeding - You have active infections or uncontrolled medical conditions - You have brain metastases causing symptoms Talk to your doctor to see if this trial is right for you.